{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:21Z","timestamp":1787027901477,"version":"build-2736575974"},"reference-count":39,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"London Health Sciences Centre Molecular Diagnostics Innovation and Development"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Since the identification of JAK2 V617F and exon 12 mutations as driver mutations in polycythemia vera (PV) in 2005, molecular testing of these mutations for patients with erythrocytosis has become a routine clinical practice. However, the incidence of myeloid mutations other than the common JAK2 V617F mutation in unselected patients referred for elevated hemoglobin is not well studied. This study aimed to characterize the mutational landscape in a real-world population of patients referred for erythrocytosis using a targeted next-generation sequencing (NGS)-based assay. Method: A total of 529 patients (hemoglobin levels &gt;160 g\/L in females or &gt;165 g\/L in males) were assessed between January 2018 and May 2021 for genetic variants using the Oncomine Myeloid Research Assay (ThermoFisher Scientific, Waltham, MA, USA) targeting 40 key genes with diagnostic and prognostic implications in hematological conditions (17 full genes and 23 genes with clinically relevant \u201chotspot\u201d regions) and a panel of 29 fusion driver genes (&gt;600 fusion partners). Results:\u00a0JAK2 mutations were detected in 10.9% (58\/529) of patients, with 57 patients positive for JAK2 V617F, while one patient had a JAK2 exon 12 mutation. Additional mutations were detected in 34.5% (20\/58) of JAK2-positive patients: TET2 (11; 19%), DNMT3A (2;3.4%), ASXL1 (2; 3.4%), SRSF2 (2; 3.4%), BCOR (1; 1.7%), TP53 (1; 1.7%), and ZRSR2 (1; 1.7%). Diagnosis of PV was suspected in 2 JAK2-negative patients based on the 2016 World Health Organization (WHO) diagnostic criteria. Notably, one patient carried mutations in the SRSF2 and TET2 genes, and the other patient carried mutations in the SRSF2, IDH2, and ASXL1 genes. Three JAK2-negative patients with elevated hemoglobin who tested positive for BCR\/ABL1 fusion were diagnosed with chronic myeloid leukemia (CML) and excluded from further analysis. The remaining 466 JAK2-negative patients were diagnosed with secondary erythrocytosis and mutations were found in 6% (28\/466) of these cases. Conclusion: Mutations other than JAK2 mutations were frequently identified in patients referred for erythrocytosis, with mutations in the TET2, DNMT3A, and ASXL1 genes being detected in 34.5% of JAK2-positive PV patients. The presence of additional mutations, such as ASXL1 mutations, in this population has implications for prognosis. Both the incidence and mutation type identified in patients with secondary erythrocytosis likely reflects incidental, age-associated clonal hematopoiesis of indeterminate potential (CHIP).<\/jats:p>","DOI":"10.3390\/curroncol29100568","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T01:52:21Z","timestamp":1665193941000},"page":"7209-7217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mutational Landscape of Patients Referred for Elevated Hemoglobin Level"],"prefix":"10.3390","volume":"29","author":[{"given":"Pratibha","family":"Bhai","sequence":"first","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0737-3603","authenticated-orcid":false,"given":"Benjamin","family":"Chin-Yee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"},{"name":"Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"},{"name":"Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Cheong","sequence":"additional","affiliation":[{"name":"Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Matyashin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"},{"name":"Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Levy","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidin","family":"Foroutan","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-8581","authenticated-orcid":false,"given":"Alan","family":"Stuart","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4287-6708","authenticated-orcid":false,"given":"Cyrus C.","family":"Hsia","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"},{"name":"Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1829-222X","authenticated-orcid":false,"given":"Hanxin","family":"Lin","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekim","family":"Sadikovic","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Division, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Verspeeten Clinical Genome Centre, London Health Sciences Centre, London, ON N6A 5W9, Canada"},{"name":"Department of Pathology & Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Chin-Yee","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5W9, Canada"},{"name":"Division of Hematology, Department of Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmoldx.2013.07.002","article-title":"Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: A report of the Association for Molecular Pathology","volume":"15","author":"Gong","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1007\/s00277-018-3451-1","article-title":"A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs","volume":"97","author":"Pallisgaard","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis","volume":"35","author":"Williams","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2017-02-734541","article-title":"Diagnosis and classification of hematologic malignancies on the basis of genetics","volume":"130","author":"Taylor","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40291-022-00581-7","article-title":"Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies","volume":"26","author":"Bhai","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_8","first-page":"1540","article-title":"Targeted massively parallel sequencing in the management of cytogenetically normal lymphoid malignancies","volume":"26","author":"Gurkan","year":"2021","journal-title":"J. BU ON"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/ejh.13272","article-title":"Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies","volume":"103","author":"Levy","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J. Mol. Diagn."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1709064","article-title":"A Gain-of-Function Mutation in EPO in Familial Erythrocytosis","volume":"378","author":"Zmajkovic","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/03630269.2021.1943430","article-title":"A New High Affinity Hemoglobin Variant: Hb San Francisco-KP (HBB: c.104T>C)","volume":"45","author":"Tavakoli","year":"2021","journal-title":"Hemoglobin"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/HJH.0000000000002253","article-title":"Concurrent heterozygous Von-Hippel\u2013Lindau and transmembrane-protein-127 gene mutation causing an erythropoietin-secreting pheochromocytoma in a normotensive patient with severe erythrocytosis","volume":"38","author":"Negro","year":"2020","journal-title":"J. Hypertens."},{"key":"ref_14","first-page":"417","article-title":"Congenital erythrocytosis-A condition behind recurrent thromboses: A case report and literature review","volume":"79","author":"Doma","year":"2021","journal-title":"Clin. Hemorheol. Micro."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1182\/bloodadvances.2020003323","article-title":"Erythrocytosis in the general population: Clinical characteristics and association with clonal hematopoiesis","volume":"4","author":"Wouters","year":"2020","journal-title":"Blood Adv."},{"key":"ref_16","first-page":"341","article-title":"Familial erythrocytosis 2 and von Hippel-Lindau disease in the same pediatric patient","volume":"78","year":"2021","journal-title":"Bolet\u00edn M\u00e9dico Hosp. Infant. M\u00e9xico"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e23715","DOI":"10.1002\/jcla.23715","article-title":"Genetic analysis of 39 erythrocytosis and hereditary hemochromatosis-associated genes in the Slovenian family with idiopathic erythrocytosis","volume":"35","author":"Kristan","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2018-03-838235","article-title":"Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease","volume":"132","author":"Lenglet","year":"2018","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"689868","DOI":"10.3389\/fgene.2021.689868","article-title":"Identification of Variants Associated with Rare Hematological Disorder Erythrocytosis Using Targeted Next-Generation Sequencing Analysis","volume":"12","author":"Kristan","year":"2021","journal-title":"Front. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/s41375-021-01290-6","article-title":"JAK2 unmutated erythrocytosis: Current diagnostic approach and therapeutic views","volume":"35","author":"Gangat","year":"2021","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2018-06-854711","article-title":"Loss-of-function zinc finger mutation in the EGLN1 gene associated with erythrocytosis","volume":"132","author":"Sinnema","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3324\/haematol.2017.176370","article-title":"New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis","volume":"103","author":"Pasquier","year":"2018","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Jalowiec, K.A., Vrotniakaite-Bajerciene, K., Capraru, A., Wojtovicova, T., Joncourt, R., Rov\u00f3, A., and Porret, N.A. (2021). NGS Evaluation of a Bernese Cohort of Unexplained Erythrocytosis Patients. Genes, 12.","DOI":"10.3390\/genes12121951"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/03630269.2020.1720711","article-title":"Novel High Oxygen Affinity Hemoglobin Variant in a Patient with Polycythemia: Hb Kennisis [\u03b285(F1)Phe\u2192Leu (TTT>TTG); HBB: c.258T>G]","volume":"44","author":"Nabhani","year":"2020","journal-title":"Hemoglobin"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"104493","DOI":"10.1016\/j.ejmg.2022.104493","article-title":"Novel mutations in EPO-R and oxygen-dependent degradation (ODD) domain of EPAS1 genes-a causative reason for Congenital Erythrocytosis","volume":"65","author":"Loganathan","year":"2022","journal-title":"Eur. J. Med. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.bcmd.2020.102479","article-title":"Novel mutations in the EPO-R, VHL and EPAS1 genes in the Congenital Erythrocytosis patients","volume":"85","author":"Chandrasekhar","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1609987","DOI":"10.3389\/pore.2021.1609987","article-title":"rs779805 Von Hippel-Lindau Gene Polymorphism Induced\/Related Polycythemia Entity, Clinical Features, Cancer Association, and Familiar Characteristics","volume":"27","author":"Remenyi","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1182\/blood-2021-152361","article-title":"Single Centre Analysis of JAK2 V617F and Exon 12 Negative Idiopathic Erythrocytosis","volume":"138","author":"Ediriwickrema","year":"2021","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mallik, N., Jamwal, M., Sharma, R., Singh, N., Sharma, P., Bansal, D., Trehan, A., Chhabra, S., and Das, R. (2022). Ultra-rare Hb Regina (HBB:c.289C>G) with coinherited \u03b2-thalassaemia trait: Solving the puzzle for extreme erythrocytosis. J. Clin. Pathol., 1\u20132.","DOI":"10.1136\/jclinpath-2021-208013"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bjh.17223","article-title":"Uniparental disomy (UPD) of a novel bisphosphoglycerate mutase (BPGM) mutation leading to erythrocytosis","volume":"192","author":"Lazana","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_31","first-page":"E150","article-title":"Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis","volume":"97","author":"Cheong","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/bjh.16450","article-title":"ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO-defined polycythaemia vera patients","volume":"189","author":"Pettersson","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2141.2007.06741.x","article-title":"Amendment to the guideline for diagnosis and investigation of polycythaemia\/erythrocytosis","volume":"138","author":"McMullin","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fonc.2019.00321","article-title":"The Role of New Technologies in Myeloproliferative Neoplasms","volume":"9","author":"Palumbo","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:22Z","timestamp":1760143462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100568"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100568","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}